Loading...

iCoreConnect Inc.

ICCTNASDAQ
Healthcare
Medical - Healthcare Information Services
$0.02
$0.00(0.00%)

iCoreConnect Inc. (ICCT) Financial Performance & Income Statement Overview

Analyze iCoreConnect Inc. (ICCT) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
31.83%
31.83%
Operating Income Growth
-50.90%
50.90%
Net Income Growth
-100.35%
100.35%
Operating Cash Flow Growth
63.39%
63.39%
Operating Margin
-144.30%
144.30%
Gross Margin
69.95%
69.95%
Net Profit Margin
-289.93%
289.93%
ROE
2001.38%
2001.38%
ROIC
229.94%
229.94%

iCoreConnect Inc. (ICCT) Income Statement & Financial Overview

Review iCoreConnect Inc. ICCT income statement with detailed quarterly and annual figures.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$2.15M$2.79M$3.09M$2.72M
Cost of Revenue$549782.00$826990.00$606617.00$1.25M
Gross Profit$1.60M$1.96M$2.48M$1.48M
Gross Profit Ratio$0.74$0.70$0.80$0.54
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$3.69M$3.35M$4.41M$4.52M
Operating Expenses$4.37M$4.16M$9.97M$5.25M
Total Costs & Expenses$4.92M$4.99M$10.58M$5.77M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense-$599261.00$855860.00$944934.00$1.53M
Depreciation & Amortization$681633.00$806509.00$781890.00$732553.00
EBITDA-$8.39M-$4.33M-$9.17M-$2.41M
EBITDA Ratio-$3.91-$1.55-$2.97-$0.88
Operating Income-$2.78M-$2.20M-$7.49M-$3.04M
Operating Income Ratio-$1.29-$0.79-$2.42-$1.12
Other Income/Expenses (Net)-$6.77M-$3.79M-$3.41M-$1.63M
Income Before Tax-$9.55M-$5.99M-$10.90M-$4.67M
Income Before Tax Ratio-$4.45-$2.15-$3.53-$1.71
Income Tax Expense$0.00$0.00$0.00$54000.00
Net Income-$9.55M-$5.99M-$10.90M-$4.72M
Net Income Ratio-$4.45-$2.15-$3.53-$1.73
EPS-$26.14-$16.40-$31.65-$13.95
Diluted EPS-$26.14-$16.40-$31.65-$13.95
Weighted Avg Shares Outstanding$365251.00$365251.00$344240.00$338486.00
Weighted Avg Shares Outstanding (Diluted)$365251.00$365251.00$344240.00$338486.00

The company's financials show resilient growth, with revenue advancing from $2.72M in Q1 2024 to $2.15M in Q4 2024. Gross profit remained healthy with margins at 74% in Q4 2024 compared to 54% in Q1 2024. Operating income hit -$2.78M last quarter, sustaining a consistent -129% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$8.39M. Net income dropped to -$9.55M, while earnings per share reached -$26.14. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;